BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-13 4:08 pm Purchase | 2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 7,382,642 14.200% | 3,375,229 (+84.22%) | Filing |
| 2024-02-14 09:56 am Unchanged | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,007,413 9.400% | 0 (Unchanged) | Filing |
| 2022-06-21 4:53 pm Purchase | 2022-06-16 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,007,413 12.400% | 2,001,551 (+99.79%) | Filing |
| 2021-07-06 5:01 pm Purchase | 2021-06-25 | 13G | 4D Molecular Therapeutics, Inc. FDMT | BIOTECHNOLOGY VALUE FUND L P | 2,005,862 7.500% | 2,005,862 (New Position) | Filing |